Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes
10.3971/j.issn.1000-8578.2021.20.1020
- VernacularTitle:输血依赖型较低危组骨髓增生异常综合征的治疗进展
- Author:
Yue FENG
1
;
Xingchun LUO
;
Yu ZHU
;
Bei LIU
Author Information
1. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China
- Publication Type:Research Article
- Keywords:
Transfusion-dependency;
Lower-risk myelodysplastic syndromes;
Small-molecule inhibitors
- From:
Cancer Research on Prevention and Treatment
2021;48(4):409-413
- CountryChina
- Language:Chinese
-
Abstract:
At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development of precise medical treatment of MDS has been promoted. Small-molecule inhibitors, such as transforming growth factor β inhibiter, telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor, provide novel therapeutic strategies for patients. This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents.
